Stockhead’s Sarah Hughan sits down with PharmAust (ASX:PAA) managing director Dr Michael Thurn to get the short end of the long story on the company’s latest news.
The biotech has requested Orphan Medicinal Product Designation in the EU for its drug to treat amyotrophic lateral sclerosis, the most common form of motor neurone disease.
It already received the same designation from the US Food and Drug Administration earlier this year.
Tune in to hear PharmAust’s Dr Michael Thurn on the debilitating disease, the pathway to drug approval, and more.
This video was developed in collaboration with PharmAust, a Stockhead advertiser at the time of publishing.
The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.
The post Long Shortz with PharmAust: Sweet incentives for sad disease’s drug development appeared first on Stockhead.
